Aging biomarkers take center stage at Shanghai longevity forum
How do you measure whether an anti-aging treatment works without waiting decades for results? That was the central question at a major international gathering on aging science.
In late September 2025, around 2,500 scientists, clinicians, and researchers from 16 countries convened in Shanghai for the TimePie Longevity Forum. It was the sixth edition of this forum, which aims to bridge fundamental laboratory research and clinical applications.
This year’s focus was aging biomarkers: measurable signals in the body that indicate how fast someone is aging biologically. The researchers and speakers discussed how such biomarkers can be used to test interventions in humans without waiting for visible health problems to appear. That is crucial, because most human aging studies take too long to yield quick conclusions.
From laboratory to clinical application
One of the biggest challenges in the field is the gap between what works in cell cultures or animals and what produces measurable effects in humans. Aging biomarkers, such as biological clocks (methods that estimate biological age based on chemical modifications to DNA), can help bridge that gap. They offer a faster readout than traditional endpoints such as disease onset or death.
The forum placed emphasis on validating these biomarkers: are they reliable, reproducible, and sensitive enough to detect changes caused by an intervention? These are not trivial questions. Previous research has shown that aging clocks do not all measure the same thing and respond inconsistently to interventions.
Translating biomarkers into treatment
Another focus was the use of biomarkers to select participants for clinical trials. By enrolling only people whose aging biomarkers already show deviation from the norm, researchers can measure treatment effects earlier and more precisely. That makes clinical aging research more efficient.
The conference report, published in Nature Aging, summarizes discussions and recommendations. It is a meeting report, not primary research; the recommendations are based on expert consensus rather than new data. But they offer a clear picture of where the field aims to go.
Search terms for further research: aging biomarkers clinical research, biological clock validation intervention, geroscience translational research